Association of Increased Fibrin Turnover and Defective Fibrinolytic Capacity with Leg Atherosclerosis

Summary

Patients with peripheral arterial disease have a high risk of death from cardiovascular events. As defective fibrinolysis associated with leg atherosclerosis has been suggested as a predisposing factor, we sought a relation among decreased fibrinolysis, the presence of leg atherosclerosis and the incidence of thrombotic events in a case control study nested in the PLAT.

Fifty-eight patients with coronary and/or cerebral atherothrombotic disease, free of leg atherosclerosis at Doppler examination, were compared with 50 atherosclerotic patients with leg involvement. High D-dimer (153.0 vs 81.3 ng/ml, p <0.001) and tPA antigen before venous stasis (14.4 vs 11.8 ng/ml, p <0.03), and low tPA antigen (6.7 vs 15.6 ng/ml, p <0.01) and fibrinolytic activity released after venous stasis (fibrinolytic capacity: 113.2 vs 281.4 mm2, p <0.001) were found in patients with leg atherosclerosis. D-dimer and fibrinolytic capacity, in addition to age, were selected by stepwise discriminant analysis as characterizing patients with leg atherosclerosis. Moreover, higher D-dimer and tPA inhibitor characterized patients with leg atherosclerosis who subsequently experienced thrombotic events.

These findings constitute evidence of high fibrin turnover and impaired fibrinolytic potential in patients with leg atherosclerosis. Thus impaired fibrinolysis may contribute to the prothrombotic state in these patients.

• References

• 1 Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386
• 2 Dormandy JA, Murray GD. The fate of the claudicant. A prospective study of 1969 claudicants. Eur J Vase Surg 1991; 5: 131-133
• 3 Hertzer NR, Beven EG, Young JR, O’Hara PJ, Ruschhaupt WF, Graor RA, De Wolfe VG, Maljovec CC. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984; 199: 223-233
• 4 Jelnes R, Gaardsting O, Jensen KH, Baekgard N, Tonnesen KH, Schroeder L. Fate in intermittent claudication. Outcome and risk factors. Br Med J 1986; 293: 1137-1144
• 5 Mats O, Bo H, Sven-Olof I, Lars J, Gudrun J, Sven-Eric L. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet 1993; 342: 1138-1141
• 6 Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Della Volpe A, Polli E. the PLAT Study Group. The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb 1992; 12: 1063-1070
• 7 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardil-lo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tre-moli E, Pozzoli E, Turri M. the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993; 13: 1412-1417
• 8 Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Della Volpe A, Polli E. the PLAT Study Group. The PLAT study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis 1991; 90: 109-118
• 9 Clauss A. Gerinnungsphysiologische Schnell-Methode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 231-246
• 5 Conover WJ. Practical non parametric statistics. 2nd Edition. New York: John Wiley & Sons Inc 1980
• 11 Al-Zahrani H, Lowe GDO, Douglas JT, Cuschieri R, Pollock JG, Smith WCS. Increased fibrin turnover in peripheral arterial disease: comparison with a population study. Clin Hemorheol 1992; 12: 867-872
• 12 Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-1742
• 13 Bertele V, Mussoni L, Del Rosso G, Pintucci G, Carriero MR, Merati MG, Libretti A, de Gaetano G. Defective fibrinolytic response in atherosclerotic patients. Effect of iloprost and its possible mechanism of action. Thromb Haemost 1988; 60: 141-144
• 14 Ridker PH, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168
• 15 Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993 88 (part 1) 2030-2034
• 16 Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationship between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63: 82-86
• 17 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl Med J 1992; 326: 310-318
• 18 Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-86